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KAJIAN POTENSI GELUCIRE 44/14 UNTUK MENINGKATKAN 
BIOKEPEROLEHAN ORAL DENGAN MENGGUNAKAN DUA DRUG MODEL 
 
ABSTRAK 
 
 
Dua drug model yang termasuk dalam dua kumpulan Biopharmaceutics 
Classification System (BCS) yang berbeza, iaitu vancomycin (VCM), satu 
sebatian kelas III (keterlarutan tinggi dan ketelapan rendah), dan griseofulvin, 
satu drug kelas II (keterlarutan rendah and ketelapan tinggi) telah digunakan 
untuk menilai potensi satu pembawa gliserida berpoliglikol, iaitu Gelucire 44/14, 
untuk meningkatkan biokeperolehan oral. Kedua-dua model drug tersebut 
berjaya digabungkan ke dalam pembawa berlipid tersebut dengan 
menggunakan teknik lebur-cantum, dengan menghasilkan penyebar pepejal 
dalam kedua-dua kes. Analisis termo yang dilaksanakan dengan menggunakan 
teknik DSC, telah mengesahkan ketiadaan kesan penuaan yang ketara bagi 
formulasi VCM-Gelucire 44/14 dan ketiadaan interaksi fizikal antara VCM 
dengan Gelucire. Kajian Fourier-Transform Infrared (FTIR) mengesahkan 
keserasian VCM dengan Gelucire 44/14. Kajian pelarutan yang telah dijalankan 
dalam media pH1, pH4 dan pH7 menunjukkan tiada perubahan yang signifikan 
dalam kadar ataupun takat pelepasan VCM daripada matriks Gelucire 44/14 
dalam ketiga-tiga media yang telah dikaji. Analisis DSC ke atas formulasi GF-
Gelucire 44/14 menunjukkan bahawa GF telah disebarkan dengan sekata 
dalam penyebar pepejal. Kajian in vivo ke atas formulasi VCM-Gelucire 44/14 
tidak menunjukkan sebarang peningkatan dalam biokeperolehan VCM. 
Sebaliknya, kajian in vivo formulasi GF-Gelucire 44/14 menunjukkan 
peningkatan biokeperolehan sebanyak 45% apabila tikus diberi formulasi GF-
Gelucire 44/14 dibandingkan dengan pemberian ampaian berair drug, dan 
 xxiii
dengan ini, fungsi Gelucire 44/14 sebagai peningkat 
biokeperolehan/penyerapan untuk drug kelas II telah disahkan. 
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INVESTIGATION OF THE POTENTIAL OF GELUCIRE 44/14 FOR 
ENHANCING ORAL BIOAVAILABILITY USING TWO MODEL DRUGS 
 
ABSTRACT 
 
 
Two model drugs belonging to different groups of the Biopharmaceutics 
Classification System (BCS), which are vancomycin (VCM) as a class III drug 
(high solubility and low permeability) and griseofulvin (GF) as a class II drug 
(low solubility and high permeability), were employed to evaluate the potential of 
a polyglycolised glyceride carrier, namely Gelucire 44/14, to enhance their oral 
bioavailability. Each of the two model drugs was successfully incorporated into 
the lipid carrier using the melt-fusion technique, producing solid dispersions in 
both cases. The thermal analysis, performed using Differential Scanning 
Calorimetry (DSC) technique, confirmed the absence of significant aging of the 
VCM-Gelucire 44/14 formulation and physical interactions of VCM with Gelucire 
44/14 were found to be not present. Fourier-Transform Infrared (FTIR) 
investigations confirmed the compatibility of VCM and Gelucire 44/14. The 
dissolution studies, performed in pH1, pH4 and pH7 media showed no 
significant changes in the rate or extent of release of VCM from the Gelucire 
44/14 matrix in any of the three media investigated. DSC analysis of the GF-
Gelucire 44/14 formulation suggested that GF was finely dispersed in the solid 
dispersion. In vivo investigations of the VCM-Gelucire 44/14 formulation did not 
show an increased bioavailability of VCM. On the other hand, in vivo studies of 
GF showed a 45% increase in bioavailability when fed to rats as GF-Gelucire 
44/14 formulation compared to aqueous suspension of the drug, thus confirming 
the role of Gelucire 44/14 as bioavailability/absorption enhancer for class II 
drugs. 
 1
CHAPTER 1 
INTRODUCTION 
 
 
1.0 Oral Delivery of Drugs 
 
An analysis of the drug delivery market reveals that oral products 
dominate more than half of it, reflecting their position as the preferred mode of 
drug administration (Brayden and O’Mahony, 1998). This preference stems 
from the ease of administration and convenience that this route imparts to the 
patients, leading to enhanced patient compliance. However, a drug that is 
delivered this way travels along the gastro-intestinal tract (GIT) and may or may 
not be absorbed into the systemic circulation depending on its fate after being 
acted upon by enzymes and other secreted substances, and its penetration 
through the epithelial cells. 
 
The luminal surface of the GIT is covered by a single layer of columnar 
epithelial cells, which is interspersed with specialized cells such as goblet cells, 
endocrine cells and M cells. Spaces between adjacent epithelial cells are term 
the “tight junctions” and make up less than 1% of the intestinal surface area 
(Yeh et al., 1998). Macromolecules such as peptides can be transported 
through this paracellular pathway via aqueous channels (Figure 1.1). 
Transcellular pathway, on the other hand, involves passive transcellular 
transport, carrier-mediated transport and endocytosis/transcytosis. 
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Figure 1.1: Potential pathways for peptide-like agents across intestinal 
epithelia.  
1 Minor paracellular route, 2 Receptor-mediated transcytosis, 3 Carrier / 
transporter-mediated, 4 Passive absorption across apical membrane and may 
or may not be followed by P-gp efflux, and 5 Carrier / transporter-mediated 
basolateral efflux (adapted from Brayden and O’Mahony, 1998) 
 
 
 
 
 
 
 
 
 
 
 
1.1 Delivery of Biopharmaceuticals  
H+
1 3 4 2 
5 
Apical 
Basolateral 
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The importance of biopharmaceuticals is affirmed by their representation 
in approximately one in every four truly new molecular entities (NMEs), with 
sales going beyond the €30 billion mark annually (Walsh, 2005). Currently, 
biopharmaceuticals such as recombinant erythropoietin (EPO), human growth 
hormone (rhGH) and low molecular weight heparin are only available as 
injectables, and it is the target of drug delivery companies to produce novel oral 
formulations of these agents (Brayden and O’Mahony, 1998). Parenteral 
administration of peptides and protein drugs is associated with poor patient 
compliance in chronic conditions, which restricts its clinical usefulness (Lee and 
Sinko, 2000). There have been numerous investigations into viable routes of 
delivery for biopharmaceuticals as alternatives to the parenteral route. These 
include the pulmonary route through inhalation therapy, transdermal route 
through the usage of chemical permeability enhancers or electricity, or through 
the mucous membranes of the buccal, nasal, vaginal and rectal localities (Pettit 
and Gombotz, 1998). In spite of the availability of other delivery routes, the most 
popular way is through the oral route due to its ease of administration and better 
patient compliance to it during long-term therapy. Thus, in this introduction 
section, the review and discussion is focussed on the oral drug delivery route. 
 
Despite the popularity of this route, the obstacles to successful oral 
delivery are numerous. Peptides can be degraded in the acidic environment of 
the stomach and metabolised by the luminal, brush border and cytosolic 
peptidases. The size, charge and hydrophilicity of peptides can adversely affect 
its permeability across the intestinal epithelium. Gastric transit time, dilution in 
GIT media and interaction with the contents of the intestine can interfere with 
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the contact between the peptides and the most absorptive part of the epithelium 
for it. The peptides can still be acted upon even after leaving the GIT, as the 
first-pass metabolism and entero-hepatic shunt elevates the risk of the peptides 
to be degraded. These factors contribute to the oral bioavailability of peptide 
drugs being typically less than 1-2% (Amidon and Lee, 1994; Zhou, 1994; 
Lagguth et al., 1997). Due to these factors, oral drug delivery achievements 
associated with proteins and peptides have been limited, with the exception of 
cyclosporin (Haeberlin et al., 1996), a cyclic lipophilic peptide. 
 
Some of the strategies adopted to circumvent these problems include 
applying enteric coating to the dosage form so that the drug remains protected 
from the harsh gastric environment by the intact polymer shell until it reaches 
the region of its absorption (Lee and Sinko, 2000). Proteolytic enzymes present 
in the small intestine will nevertheless limit the utility of this method (Lee and 
Yamamoto, 1990; Bai and Amidon, 1992; Woodley, 1994), unless protease 
inhibitors are delivered together, the local pH value is adjusted to the pH minima 
of the intestinal enzymes, or the enzymes are saturated by sustaining high drug 
concentrations (Friedman and Amidon, 1991; Bai et al., 1995; Bai et al., 1996). 
A reduction in intestinal pH by citric acid had led to the stabilisation of the 
administered salmon calcitonin, which in turn resulted in a higher oral 
absorption (Lee et al., 1999). Absorption promoters that transiently and 
reversibly open the tight-junctions in the epithelium or that enhance delivery to 
the lymphatic system by forming chylomicrons could also be used. The use of 
absorption enhancers are not without risks as each class of agents has its 
associated adverse effects. Sodium taurodeoxycholate, lauroyl carnitine 
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chloride, Tween 80, myristoyl carnitine chloride among others, have been 
shown to promote the intestinal uptake of calcitonin but have also been linked to 
a reduction in transepithelial electrical resistance, indicating an acute toxic 
effect (Sinko et al., 1999). Medium chain glycerides have also been shown to 
enhance intestinal permeability (Yeh et al., 1994; Yeh et al., 1995) but it was not 
clear whether the effect was via the paracellular pathway or the transcellular 
pathway. Tzan et al. (1993) have demonstrated that polypeptides with positive 
charge could cause increases in the tight junctional permeability but no similar 
effect was observed with negative or neutral polypeptides.  
 
Other strategies include targeting receptors at the brush border of the 
intestine so that the biopharmaceutical would be uptaken upon the receptor 
activation. Enzyme-resistant peptide analogues could be synthesised to 
overcome the problem of peptide digestion. Bioadhesive formulations would 
allow peptides to be in contact with its most absorptive site without being 
prematurely cleared by gastrointestinal transit (Venkatesan et al., 2006). 
Releasing the peptides in the colon would also be advantageous as the colon 
has a lower level of peptidases than ileum and the transit is slower in this part 
of the GIT. The peptides could be encapsulated in a polymeric casing that can 
be degraded by the bacterial flora in the colon, and this type of release offers 
the additional benefit of the time of release being more reliable as it is 
dependent on the local physiology, rather than timed release which could be 
affected by the variability of transit times between individuals. Pro-drugs, which 
are more hydrophobic and permeable could also be synthesised. Once inside 
the intestinal cells, the esterases in the cytosol would cleave particular linkages 
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to release the active peptides. More recently, the use of P-glycoprotein and 
cytochrome P450 3A inhibitors to suppress efflux and metabolism respectively 
has been investigated (Brayden and O’Mahony, 1998; Lee and Sinko, 2000). 
 
1.2 Drug Delivery Systems 
 
The importance of drug delivery strategies in formulating products with 
favourable properties has been heightened in the advent of biopharmaceuticals 
and other new chemical entities (NCE) with low solubility or permeability. 
Previously, work on drug delivery was centred on making existing drugs more 
effective or tolerable, as well as enhancing the ease of administration. More 
recently however, drug delivery techniques are incorporated at an earlier stage 
of the product development, with a view to turning the more “difficult” new drugs 
or compounds that traditionally would have been deemed as “failed” and 
discarded, into successful pharmaceutical products (Rosen and Abribat, 2005). 
With pharmaceutical research and development costs per approved agent 
estimated to be US$400-US$800 million (DiMassa et al., 2003), it is of little 
surprise that the drug delivery approach is increasingly adopted to elevate the 
probability of success. In addition, formulating existing and classical drugs after 
the expiry of their patents, using new delivery technologies can further expand 
the drug market (Orive et al., 2004). Such a potential can be illustrated by 
ceftriaxone, a third-generation cephalosporin antibiotic, which has properties of 
a class III drug according to the Biopharmaceutics Classification System (BCS), 
as defined by Amidon et al. 1995 (see Table 1.1). When the anionic ceftriaxone 
was physically complexed with a cationic analogue of deoxycholic acid and 
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formulated with propylene glycol, the oral bioavailability in rats was increased 
up to 70% due to the antibiotic being made more hydrophobic (Lee et al., 2005). 
 
Table 1.1: The Biopharmaceutics Classification System (adapted from Amidon 
et al., 1995) 
 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
 
As previously discussed, biopharmaceuticals represent a challenge to 
the drug delivery field and various techniques have been devised to promote 
success especially in oral delivery. One example of such methods is the 
formation of biodegradable nano- and microparticles. The polymers used will 
slowly degrade, releasing drugs such as leuprorelin acetate or recombinant 
human growth hormone at a sustained rate, resulting in improved bioavailability. 
The minuteness of these systems promotes higher intracellular uptake, and 
covalently attaching folic acid to the surface to target folate receptors, can 
further enhance such uptake (Orive et al., 2004). Being of such sizes could also 
allow the particles to move across the intestinal lining through the Peyer’s 
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patches, which form part of the intestinal lymphatic system. It has been 
demonstrated that microspheres of about 100nm in size made from polylactic-
co-glycolic acid (PLGA) could be taken up into Peyer’s patches, with the 
efficiency of the uptake being 15-250 fold higher than larger particles. Peyer’s 
patches was also found to have had 2-200 fold higher uptake than non-patch 
tissue from the same intestinal region, depending on the size of the particles 
(Desai et al., 1996). When the microspheres were prepared using another 
biodegradable polymer, namely polyanhydrides, the particles demonstrated 
strong adhesive interactions with the mucous and cellular lining of the GIT. 
During their relatively long residency time at the surface of the intestinal 
epithelium, the particles were able to penetrate the cells, either paracellularly or 
transcellularly. This occurs both at the mucosal absorptive epithelium and the 
follicle-associated epithelium covering the Peyer’s patches (Mathiowitz et al., 
1997). In addition to opening up an alternative route to drug uptake, 
encapsulation of biopharmaceuticals in the form of microspheres made from 
degradable polymers has permitted the drug to be released in a more sustained 
manner, with the carrier simply breaking down into biologically inert by-
products. 
 
Incorporating lipid materials into self-dispersing formulations has become 
a popular approach to enhance oral bioavailability especially for lipophilic drugs. 
These drugs fall into the class II category of the Biopharmaceutics Classification 
System (BCS), and poor dissolution would represent the rate-limiting step in the 
absorption process. Nevertheless, lipid based formulations have been found to 
be also useful in the oral delivery of class III bioactives, such as 
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biopharmaceuticals. New et al. (1997) designed and developed a water-in-oil 
emulsion, termed the Bridgelock formulation, which was capable of increasing 
the bioavailability of salmon calcitonin in surgically manipulated pig models. The 
peptide was incorporated into the aqueous phase that contained phosphatidyl 
choline and other phospholipids, whilst the oil phase was composed of oleic 
acid, lecithin, glycerol monooleate and cholesterol. The components used in the 
emulsion were selected for their ability to stimulate lymph flow and form 
chylomicrons. Thus, in addition to passing directly into systemic blood system 
via the microvasculature surrounding the intestinal tissue that in turns feeds into 
the hepatic portal system, the peptide can associate itself to the oil phase that is 
then uptaken via the lymphatics. This was also shown by Ling and co-workers 
(2006), where the lymphatic absorption of cefotaxime liposomal formulation was 
confirmed to play a role in the increased bioavailability of this peptidomimetic 
drug. 
 
The lymphatics is an attractive system to target in drug delivery as an 
auxiliary absorption route. Lymph is estimated to flow from the intestine at a rate 
of about 100ml/hour in an active person, so that a substance contained within 
the lymph can reach the bloodstream in a short period of time due to the active 
circulation of interstitial fluid (New et al., 1997).  
 
1.2.1 Gelucire 44/14 as a Self-Emulsifying Drug Delivery System 
 
Self-Emulsifying Drug Delivery Systems (SEDDS) have been defined as 
homogenous mixtures of natural or synthetic oils, solid or liquid surfactants or 
one or more hydrophilic solvents and co-solvents (Gershanik and Benita, 2000). 
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SEDDS require nominally no energy to emulsify. As a point of interest, the first 
self-emulsifying product to reach the market was Dettol by Reckitt&Colman 
(confidential internal report). 
 
After few commercial successes, such as Sandimmune-Neoral 
(cyclosporin A), Solufen Lidose (ibuprofen), Fortovase (sequinavir) and Norvir 
(ritonavir), SEDDS received increased attention by formulation scientists as a 
useful tool to overcome the low oral bioavailability of newly discovered drugs 
characterised by low water solubility (Gursoy and Benita, 2004). In particular, a 
subset of SEDDS, which is Self-MicroEmulsifying Drug Delivery Systems 
(SMEDDS), show even better absorption due to smaller droplet sizes, as 
reviewed by Gursoy and Benita (2004). To date, one of the most common lipids 
to be associated with SMEDDS is Gelucire 44/14, which is a member of the 
polyglycolised glycerides family of excipients. 
 
Gelucire 44/14 is derived from the reaction of hydrogenated palm kernel 
oil with PEG 1500 and conforms to the requirements of the European 
Pharmacopœia 4th Edition (2002) under the “lauroyl macrogolglycerides” 
monograph. Gelucire 44/14 comprises about 20% mono-, di- and triglycerides, 
72% mono- and di- fatty acid esters of PEG 1500 and 8% of free PEG1500. A 
schematic view of the fatty acid components of Gelucire 44/14 is shown in 
Table 1.2 (Gattefossé, 1999). 
 
Gelucire 44/14 has been studied as a lipid carrier for several drugs 
characterised by low solubility. UC 781, an anti-HIV compound, has intrinsically 
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poor solubility but this was increased by formulating it with Gelucire 44/14 
(Damian et al., 2000; Deferme et al., 2002; Damian et al., 2002). However, 
problems of stability of UC 781 in the lipid matrix and aging effect of the 
formulations precluded further developments. Increased solubility was also 
obtained for the antiviral drugs DMP 323 (Aungst et al., 1997), EMD 50733 (a 
lipophilic compound with intermediate log P) which in vivo bioavailability 
registered a 10-fold increment compared to the drug/lactose mixture (Schamp 
et al., 2006) and for an undisclosed experimental compound (Joshi et al., 2004).  
 
Table 1.2: Fatty acids composition in Gelucire 44/14 (Gattefossé, 1999) 
 
Fatty acid distribution Gelucire 44/14 
Caprylic acid (C8) 4-10% 
Capric acid (C10) 3-9% 
Lauric acid (C12) 40-50% 
Myristic acid (C14) 14-24% 
Palmitic acid (C16) 4-14% 
Stearic acid (C18) 5-15% 
 
SMEDDS formulations containing Gelucire 44/14 and incorporating 
numerous other drugs such as phenytoin and indomethacin (Kawakami et al., 
2006), a ceftriaxone complex (Cho et al., 2004), piroxicam (Yüksel et al., 2003; 
Karatas et al., 2005), carbamazepine (Sethia and Squillante, 2004), griseofulvin 
(Yang et al., 2007), and halofantrine (Khoo et al., 2000; Abdul-fattah et al., 
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2002) have been investigated. Khoo et al. (2000) found that even when the 
dissolution profile of halofantrine formulated with PEG 6000 was found to be 
better than the Gelucire 44/14 formulation, the latter formulation showed 
increased bioavailability compared to the former when investigated in vivo. In a 
study of α-tocopherol (Barker et al., 2003), it was shown that the Gelucire 44/14 
formulation was able to provide a 2-fold increase in bioavailability of this 
nutraceutical compared to the commercially available preparation. 
 
In the previous instances, the aim of the researchers was to increase the 
oral bioavailability of these drugs mainly by increasing their solubility, as low 
solubility is reputed to be one of the main factors for the low bioavailability of 
poorly water-soluble drugs (Humberstone and Charman, 1997). Hauss et al. 
(1998), on the other hand, investigated a Gelucire 44/14 formulation containing 
ontazolast, also a poorly water-soluble compound, with the view to evaluate the 
lymphatic transport of the drug. Even though the SEDDS formulation provided 
the fastest absorption (lowest tmax and highest Cmax) of ontazolast, the lymphatic 
transport, however, did not appear to play a significant role in the increased 
bioavailability, possibly due to the size of the formed micelles. 
 
Koga et al. (2002) investigated the effect of Gelucire 44/14 and Labrasol 
at low concentrations on the membrane permeability of isolated rat intestine 
using cephalexin and cefoperazone as model drugs. Their results showed that 
Gelucire 44/14 did not enhance the membrane permeability of either drug as 
opposed to Labrasol, which enhanced the membrane permeability and intestinal 
absorption. Since the HLB for both Gelucire and Labrasol is 14, the effect of 
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HLB of non-ionic surfactants on membrane fluidity is not thought to be a factor 
here; instead, the enhancement by Labrasol was thought to be due to its 
promotion of the passive transport as well as the active transport via ion flux.  
The authors explained that the passive and active transports were in turn, 
affected by the particle size and polydispersity index of the emulsion droplets. It 
may be interesting to note that Labrasol is almost exclusively composed of 
caprylic and capric acids (approximately 58% and 41% respectively) while for 
Gelucire 44/14, the same two fatty acids are present as minor components (see 
Table 1.2). 
 
Delivery of protein and peptide-like biopharmaceuticals have also been 
investigated using lipid based formulations. In fact, Mori et al. (2004) studied 
Labrasol and Gelucire 44/14 as absorption enhancers using low molecular 
weight heparin as model drug and showed that the formulation containing 
Labrasol resulted in higher bioavailability of the drug. Recombinant human 
erythropoietin (rhEPO) was prepared as nanoparticles for intra-jejunal 
administration (Venkatesan et al., 2005) and patches for local delivery 
(Venkatesan et al., 2006), using Labrasol and Gelucire 44/14 in both studies; in 
both cases Gelucire 44/14 enhanced the bioavailability of rhEPO, even though 
to a lesser extent compared to Labrasol. However, their studies confirmed the 
capability of Gelucire 44/14 to increase the bioavailability of protein-based 
compounds with a mode other than simply increasing the drug solubility. Even 
though the mechanism is still not clear, it is thought that microemulsions formed 
may protect the drug from degradation/denaturation in the gastric environment. 
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The method of dosage form preparation was also thought to influence 
the overall bioavailability of the model drugs employed. Chauhan et al. (2005) 
prepared physical mixture and solid dispersion of glibenclamide and Gelucire 
44/14 and showed that the solid dispersion performed better in terms of the 
therapeutic efficacy of the drug. They related the favourable result of the solid 
dispersion to the presence of glibenclamide in the amorphous state. In another 
investigation, the cryogenically grinded powder of a solid dispersion containing 
ketoprofen and Gelucire 44/14 was evaluated against the non-grinded form 
(Chambin et al., 2004). However, it was demonstrated that these two 
preparation techniques led to non-significant difference in the in vitro release of 
ketoprofen. 
 
1.2.2 Advantages of Gelucire 44/14 
 
Lipid microemulsions have the potential to offer protection against 
enzymatic hydrolysis and may enhance absorption of drugs (Constantinides, 
1995). A schematic view about which potential microemulsion could be 
prepared for drugs belonging to the different classes of the BCS is given in 
Table 1.3. For a definition of the BCS categories please refer to Table 1.1. 
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Table 1.3: Potentially useful microemulsion for biopharmaceuticals of different 
classes of the BCS (adapted from Constantinides, 1995) 
 
Class Potential microemulsion Potential advantages 
I W/O Stabilization and protection against chemical and enzymatic hydrolysis 
II SEDDS; O/W Improved solubilisation and dissolution, increased BA 
III W/O Stabilization and protection against chemical and enzymatic hydrolysis, increased BA 
IV SEDDS; O/W Improved solubilisation and dissolution, increased BA 
 
Gelucire 44/14, being a semisolid waxy material, offers an important 
advantage over Labrasol which is in liquid form in that can be loaded into hard 
gelatine capsules. In fact, from an industrial point of view, it is more economical 
and simple to prepare liquid filled hard gelatine capsules than liquid filled soft 
gelatine capsules. 
 
1.3 Glycopeptide Antibiotics: Vancomycin 
 
Vancomycin was the first compound discovered belonging to a new class 
of antibiotics: the glycopeptides. VCM was isolated in the 1950s by Eli-Lilly in a 
culture of Nocardia orientalis (later reclassified as Amicolatopsis orientalis). 
Scientists succeeded only in the 1980s to finalise the structure of VCM due to 
its complexity and presence of a significant number of functional groups (Figure 
1.2). The general structure of glycopeptide drugs is characterised by the 
presence of a sugar linked to a polypeptide ring (Nagarajan, 1994). In particular, 
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VCM has an aminodisaccharide linked to a heptapeptide ring, which gives rise 
to the possibility of multiple charges once ionised. 
 
VCM is an amphoteric molecule containing charged amino-, carboxyl- 
and phenolic groups, more specifically: three phenolic groups with pKa1 10.6, 
pKa2 10.3 and pKa3 9.4; two amino groups (as N-terminal and aminosugar, 
respectively) with pKa1 8.6 and pKa2 6.8; one C-terminal carboxylate with pKa 
2.5 (Sitrin et al., 1985).  
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Figure 1.2: Diagrammatic representation of the structure of vancomycin 
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1.3.1 Properties of Vancomycin 
 
At levels near its minimum inhibitory concentration (MIC), VCM is 
bactericidal to most of the bacteria that show susceptibility to it. The antibiotic 
achieves its function by inhibiting bacterial cell wall peptidoglycan synthesis, but 
targeting a location that is different from that of β-lactam antibiotics (Russell, 
1998). In particular, VCM inhibits bacterial cell wall synthesis at a different site 
than penicillin and cephalosporins by binding to D-Ala-D-Ala portion of the cell 
wall precursor; this leads to destruction of bacterial cell by lysis; VCM may also 
alter the permeability of bacterial cytoplasmic membranes and may selectively 
inhibit RNA synthesis (USP Drug Information 14th Ed., 1994). VCM has a half 
life, t1/2, of 2.9-9.1h (USP 24, 2000). 
 
For systemic infections, the antibiotic must be administered via the 
intravenous route as it is poorly absorbed when taken orally. VCM penetrates 
well into most body fluids except possibly aqueous humour and cerebrospinal 
fluid, and is excreted mainly via the kidneys (Moellering, 1984). In humans, 
VCM efficacy is related to the 24-hour AUC-MIC as the important 
pharmacokinetic-pharmacodynamic (PK-PD) parameter (Craig, 2003). 
 
1.3.2 Uses of Vancomycin 
 
Currently, one of the important uses of VCM is for treatment of 
methicillin-resistant Staphylococcus aureus (MRSA) infections. This intrinsic 
multidrug resistance expression by S. aureus has been postulated to be due to 
the activation of the sarA locus on the chromosome of the microorganism 
(O’Leary et al., 2004). The number of outbreaks of MRSA, up to epidemic 
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proportions, are alarmingly increasing. These usually occur in hospitals and 
once MRSA is established in the high-dependency units such as intensive care, 
burns and cardiothoracic units, the pathogen then spreads readily to the rest of 
the patients and hospital staff. Together with teicoplanin, another glycopeptide 
antibiotic albeit about three times more expensive, vancomycin remains as the 
recommended treatment for these infections (Finch, 1998). Intravenous 
antimicrobials are generally more expensive than the oral forms, thus 
compounding to the factor that the glycopeptides are already more costly than 
aminoglycosides and beta-lactam antibiotics. Their increasing inclusion in 
treatment protocols will have a clear economic impact on health systems 
(Janknegt, 1997). 
 
MRSA can cause complicated skin and soft tissue infections which 
treatment will most probably involve hospitalisation. In addition to the cost of the 
medications to be given to the infected patients, prolonged hospital stay will 
present another substantial economic burden to the health care system. 
Advocating earlier hospital discharge will greatly reduce the overall costs 
(Nathwani, 2003). A novel oxazolidinone antibiotic, linezolid, had been 
demonstrated in a clinical trial to be as effective as vancomycin in MRSA 
infections. The difference between the two antibiotics is that linezolid is 100% 
bioavailable in oral forms whereas vancomycin is not absorbed. When the two 
drugs were compared head to head in a randomised clinical study that 
evaluates the length of hospital stay of patients with complicated skin and soft 
tissue infections, linezolid was found to reduce the number of days in hospital 
significantly (Li et al., 2003), with increased chances of being discharged within 
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the first week of hospitalisation (Nathwani, 2003). This could be due in part to 
the patients receiving linezolid being able to follow up on their intravenous drug 
administration with oral medication, which they may take at home, as opposed 
to the intravenous only vancomycin that often means confinement in the wards. 
It has been previously suggested that if patients were allowed to leave the 
hospital and complete their therapy with an oral formulation of a highly 
bioavailable antibiotic, a reduction in treatment costs could be achieved in 
addition to improving the efficacy of existing older antimicrobial agents 
(Niederman, 2001). This protocol was repeated in a multinational, multicentre, 
randomised clinical study and a comparable result to the above was found, with 
patients treated with linezolid significantly spending less time in hospitals 
compared to those treated with vancomycin and significantly more patients on 
linezolid being discharged within the first two weeks (Itani et al., 2005). 
 
VCM powder for injection dissolved in phosphate buffer (Itoh et al., 
2001), normal saline or phosphate buffered artificial tears (Fleischer et al., 
1986) was found to be effective against MRSA in eye infections. When 
formulated with Pluronic F-127 (ethylene oxide and propylene oxide), the drug 
was able to be applied into the ear for the treatment of chronic otitis media 
caused by MRSA (Lee et al., 2004). The polymer solution exists as a liquid at 
room temperature allowing it to be drawn into a syringe, and once subjected to 
higher temperatures such as the body temperature inside the ear, the 
formulation changes into a gel from which VCM can be released in a sustained 
manner. 
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Another of VCM uses is for the treatment of osteomyelitis, which could 
have come about as a consequence of open fractures or surgery. Indeed, many 
of the more recent research involving VCM and formulation of delivery systems 
for the drug have been centred on this field of concentrating this anti-
staphylococcal agent in the bone area. A localised VCM delivery system 
involving implantantion of drug loaded chitosan microspheres has been 
described (Cevher et al., 2006). Biodegradable microspheres were obtained by 
mixing the chitosan solution with VCM and spray drying the mixture. By 
targeting the drug at the potential site of infection, side effects associated with 
systemic toxicity could be avoided and the biodegradability of the polymer used 
eliminates the need of surgical removal of the implant.  
 
The use of an alternative polymer, poly(lactide-co-glycolide), has also 
resulted in a successful formulation of biodegradable microparticles loaded with 
VCM for bone implantation (Billon et al., 2005). A sustained drug release over 
10 days was reportedly achieved using this delivery system and the workers 
postulated that the microparticles could be injected together with biphasic 
calcium phosphate granules to form a bone substitute. Earlier investigations 
(Iooss et al., 2001; Le Ray et al., 2003) had resulted in the development of VCM 
loaded poly(ε-caprolactone) microparticles. The 200μm sized microparticles 
were obtained through simple emulsion evaporation/extraction process with 
manual dispersion of the drug, and together with biphasic calcium phosphate 
granules formed an injectable bone substitute that was capable of releasing the 
VCM at a controlled rate, hence eliminating the risk of infection at the site of 
implantation. 
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One of the commonest nosocomial infections are post-operative 
infections and VCM is the drug of choice to counter these surgical complication 
when methicillin-resistant S. aureus and S. epidermidis are implicated (de Lalla, 
1999). Such complication becomes more pronounced in cases where a foreign 
object is introduced into the body and left there for an indefinite duration of time. 
A literature search with the keywords of “vancomycin” and “drug delivery” 
reveals a plethora of work focussing on prostheses or devices impregnated with 
VCM by Chilukuri and Shah (2005), Kelm et al. (2006) amongst others, various 
slow-release systems designed to be applied to the potentially affected site by 
Radin et al. (1997), Drognitz et al. (2006) amongst others, and matrices to treat 
osteomyelitis, a few of which have been outlined above.  
 
The intensifying efforts in this field demonstrate that research 
laboratories are cognisant of the substantially increasing VCM use in the last 
few years due to colonisation of bone and prosthetic devices by MRSA. A sol-
gel formulation of VCM in Poloxamer 407 (polyoxyethylene-polyoxypropylene) 
was found to release adequate amounts of the antibiotic to be effective against 
S. aureus even up to eight days in vivo in rats. At low temperatures, the 
formulation is in liquid form, allowing it to be drawn up into a syringe and 
administered to the tissue surrounding a foreign body. At body temperature, the 
formulation changes into a semisolid gel from which VCM is released in a 
sustained manner (Veyries et al., 1999), not unlike the VCM in Pluronic F-127 
previously described (Lee et al., 2004). Moreover, the Poloxamer 407 
formulation is thought to be capable of preventing the adhesion of bacteria to 
the foreign object in the body. 
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In paediatric medicine, VCM is still the treatment of choice for severe 
MRSA infections (Ladhani and Garbash, 2005). VCM is also given as an 
adjunct in the management of febrile neutropenia when first-line empirical 
therapy has failed (Ziglam et al., 2005). The emergence of Streptococcus 
pneumoniae, which is resistant to many antibiotics, was thought to be in part 
due to over-exposure to these antimicrobials especially in relation to the 
respiratory tracts of children. Morbidity and mortality occurs significantly when 
the infection with this microorganism causes pneumonia and meningitits. 
Resistant pneumococcal infections occur at a higher rate amongst patients with 
malignancies, HIV co-infection and sickle cell disease. VCM is the only 
antimicrobial that the microorganism has not shown resistance to (Jacobs, 
2004). 
 
Since VCM is poorly absorbed when given via the oral route, the 
intravenous route has been the only option for treating generalised systemic 
infection (Moellering, 1984). Oral use of VCM has so far been restricted to the 
treatment of local infections in the gastrointestinal tract (GIT). A and B toxins, 
produced by Clostridium difficile, can cause pseudomembranous colitis and 
drug therapy indicated for this is oral vancomycin, 125mg four times daily for 10 
days (Farthing et al., 1994). Conversely, inflammatory bowel diseases such as 
the Clostridium difficile induced enterocolitis can actually lead to an increased 
absorption of oral VCM (Cadle et al., 2006). Novel oral formulations, such as 
the one described by Musenga et al. (2005), frequently focuses on the delivery 
of VCM to a particular site of infection in the GIT. Albumin nanospheres loaded 
with the antibiotic and coated with stearic acid were found to give adequate 
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protection to the drug and release the drug at the targeted site, colon. On 
another note, oral VCM has been associated with an improvement in children 
with late-onset autism, as this condition may involve the presence of abnormal 
flora in the GIT (Finegold et al., 2002).  
 
1.3.3 Other Formulations of Vancomycin 
 
Microcapsules made from poly d,l-lactic acid (PLA) and poly(D,L-lactide-
co-glycolide) (PLGC) and loaded with VCM were prepared through the 
formation of water-oil-water (w/o/w) double emulsion and solvent evaporation 
technique. The bactericidal effect on S. aureus were found to be sustained for 4 
days (Ozalp et al., 2001) but it was unclear what the final route of administration 
or target site of the microcapsules would be. Other VCM w/o/w emulsions were 
prepared either from sesame oil and monoglycerolstearate (Shively and 
Thompson, 1995) or using Lipiodol-isopropyl myristate for IM administration 
(Okochi and Nakano, 2000). Even if the relative BA of VCM was significantly 
increased, these formulations were of complex preparation and stability issues 
were unresolved. 
 
A self-micro-emulsifying (SMEDDS) formulation of VCM was prepared 
using Labrasol and D-α-tocopheryl-PEG 1000 succinate by Rama Prasad et al. 
(2003) and, once administered intraperitoneally, showed significant plasmatic 
levels of VCM compared to the saline solution. However stability data of the 
formulation are not available. 
 
